Unlike conventional vaccines, nirsevimab — a new RSV shot for infants — is a monoclonal antibody. Its widespread use in children is unprecedented, and long-term safety data is limited.
Unlike conventional vaccines, nirsevimab — a new RSV shot for infants — is a monoclonal antibody. Its widespread use in children is unprecedented, and long-term safety data is limited.
What safety data. That is a joke. It is just right to the market now. Real time is how it goes now. We are just lab rats.
https://theconversation.com/covid-19-flu-and-rsv-shots-an-epidemiologist-explains-why-all-three-matter-this-fall-237443
The article I just saw today. Full steam ahead.